Analysts Set Shattuck Labs, Inc. (NASDAQ:STTK) Price Target at $4.00

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $4.00.

Several brokerages have commented on STTK. Wedbush initiated coverage on shares of Shattuck Labs in a report on Monday, September 8th. They issued an “outperform” rating and a $4.00 price objective for the company. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Shattuck Labs from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Shattuck Labs in the 3rd quarter worth about $29,000. Virtu Financial LLC bought a new stake in Shattuck Labs during the third quarter worth about $38,000. AQR Capital Management LLC grew its holdings in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Shattuck Labs during the second quarter valued at approximately $44,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Shattuck Labs during the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $3.17 on Wednesday. The stock’s 50-day moving average is $2.30 and its 200 day moving average is $1.65. The company has a market cap of $200.60 million, a PE ratio of -3.11 and a beta of 1.70. Shattuck Labs has a 1 year low of $0.69 and a 1 year high of $3.38.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue of $1.00 million during the quarter. Analysts expect that Shattuck Labs will post -1.48 EPS for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.